Standard Treatments for HR+/HER2- mBC in 2023

November 14, 2023
Disclaimer: "This video was recorded prior to the FDA approval on November 16, 2023, of capivasertib with fulvestrant for HR+/HER2- locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy"
Login to view comments. Click here to Login